Multiple sclerosis and related disorders · 2026
Validation of a new diagnostic ELISA to detect anti-JCV antibodies in serum of patients with multiple sclerosis considering or receiving treatment with natalizumab.
СтатьяВалидационное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Adler Fred, Andersen Mike, Bartl Tobias, Derlacz Rafał, Frese Marc-Andre, Keller Thomas, Schelcher Celine, Wiegand Rick
Аннотация
BACKGROUND: Anti-John Cunningham virus (JCV) antibody testing is integral to progressive multifocal leukoencephalopathy (PML) risk stratification in patients with multiple sclerosis (MS), considering or receiving natalizumab. We report on analytical and clinical validation of the two-step ImmunoWELL JCV enzyme-linked immunosorbent assay (ELISA) for anti-JCV antibody testing in this patient population.
METHOD: Assay cut-off points were established using MS patient sera (N = 329), with a combined test strategy incorporating a screening test with a percentage inhibition test for those screening in an 'equivocal zone'. Clinical performance was evaluated in sera from 888 patients with MS (blinded) against STRATIFY® JCV DxSelect™ (the 'reference test'), with primary endpoints of sensitivity and specificity.
RESULTS: Variability (imprecision) was low (total coefficient of variation 6.5-11.3%); samples were stable, and no relevant hook effect was observed. Cross-reactivity was also analyzed. The optimized cut-off strategy achieved 96.4% sensitivity and 80.9% specificity. In the clinical validation study, sensitivity was 97.2%, specificity 74.1%, positive predictive value 83.5%, and negative predictive value 95.3%. Polymerase chain reaction-based false-negative estimates were similar between the ImmunoWELL JCV test (1.6%) and the reference test (3.3%). Reported serostatus change (17.3% vs 15.8%, respectively) and seroconversion (6.7% vs 10.1%, respectively) were comparable between assays.
CONCLUSIONS: The ImmunoWELL JCV test is a reliable two-step ELISA with high sensitivity and clinically relevant specificity versus the reference test, supporting its use to inform PML risk management in patients with MS considering, or receiving, natalizumab.
METHOD: Assay cut-off points were established using MS patient sera (N = 329), with a combined test strategy incorporating a screening test with a percentage inhibition test for those screening in an 'equivocal zone'. Clinical performance was evaluated in sera from 888 patients with MS (blinded) against STRATIFY® JCV DxSelect™ (the 'reference test'), with primary endpoints of sensitivity and specificity.
RESULTS: Variability (imprecision) was low (total coefficient of variation 6.5-11.3%); samples were stable, and no relevant hook effect was observed. Cross-reactivity was also analyzed. The optimized cut-off strategy achieved 96.4% sensitivity and 80.9% specificity. In the clinical validation study, sensitivity was 97.2%, specificity 74.1%, positive predictive value 83.5%, and negative predictive value 95.3%. Polymerase chain reaction-based false-negative estimates were similar between the ImmunoWELL JCV test (1.6%) and the reference test (3.3%). Reported serostatus change (17.3% vs 15.8%, respectively) and seroconversion (6.7% vs 10.1%, respectively) were comparable between assays.
CONCLUSIONS: The ImmunoWELL JCV test is a reliable two-step ELISA with high sensitivity and clinically relevant specificity versus the reference test, supporting its use to inform PML risk management in patients with MS considering, or receiving, natalizumab.